Literature DB >> 23800570

Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium-a meta-analysis.

Bertrand N Mukete1, Clive Rosendorff2.   

Abstract

This study is a meta-analysis of the metabolic profile (fasting plasma glucose and serum potassium) of low-dose thiazide and thiazide-like diuretics. The meta-analysis involved 10 randomized controlled clinical trials with a total sample size of 17,636 and 17,947 for the potassium and glucose arms respectively. The random effect model was used to calculate the odds ratio with 95 percent confidence interval. The cumulative mean change of fasting plasma glucose was +0.20 mmol/L (+3.6 mg/dL) for the diuretic arm versus +0.12 mmol/L (+2.2 mg/dL) for the comparator arm. The cumulative mean change of serum potassium was -0.22 mmol/L (-0.22 mEq/L) for the diuretic arm versus +0.05 mmol/L (+0.05 mEq/L) for the comparator arm. The aggregate odds ratio for having higher fasting plasma glucose in subjects on low-dose thiazide versus non-thiazide antihypertensive was 1.22 (1.11 to 1.33; P < .01). The odds ratio for having a lower serum potassium in subjects on low-dose thiazide versus non-thiazide antihypertensive was 0.36 (0.27 to 0.49; P < .01). The magnitude of the observed change in fasting plasma glucose associated with low-dose thiazide diuretic use, while statistically significant, does not appear to place patients at clinically significant risk. On the other hand, the observed change in serum potassium was also statistically significant, and may be clinically significant in patients whose baseline potassium concentration is low or low-normal, and could predispose at-risk patients, such as those with ischemic heart disease, to ventricular arrhythmias. Published by Elsevier Inc.

Entities:  

Keywords:  Chlorthalidone; diuretics; glucose; hydrochlorothiazide; hypertension; hypokalemia; potassium; thiazide

Mesh:

Substances:

Year:  2013        PMID: 23800570     DOI: 10.1016/j.jash.2013.05.004

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  8 in total

Review 1.  Tolerability of Antihypertensive Medications in Older Adults.

Authors:  Thiruvinvamalai S Dharmarajan; Lekshmi Dharmarajan
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

2.  Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.

Authors:  Yao Qiao; Jung-Im Shin; Yingying Sang; Lesley A Inker; Alex Secora; Shengyuan Luo; Josef Coresh; G Caleb Alexander; John W Jackson; Alex R Chang; Morgan E Grams
Journal:  Mayo Clin Proc       Date:  2019-10-13       Impact factor: 7.616

Review 3.  Type 2 Diabetes and Thiazide Diuretics.

Authors:  André J Scheen
Journal:  Curr Diab Rep       Date:  2018-02-05       Impact factor: 4.810

Review 4.  The role of dietary potassium in hypertension and diabetes.

Authors:  Cem Ekmekcioglu; Ibrahim Elmadfa; Alexa L Meyer; Thomas Moeslinger
Journal:  J Physiol Biochem       Date:  2015-12-03       Impact factor: 4.158

Review 5.  Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Authors:  Xiaodan Zhang; Qingyu Zhao
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-09-23       Impact factor: 3.738

6.  Blood electrolyte disturbances during severe hypoglycemia in Korean patients with type 2 diabetes.

Authors:  Mi Yeon Kang
Journal:  Korean J Intern Med       Date:  2015-08-27       Impact factor: 2.884

7.  Redefining diuretics use in hypertension: why select a thiazide-like diuretic?

Authors:  Michel Burnier; George Bakris; Bryan Williams
Journal:  J Hypertens       Date:  2019-08       Impact factor: 4.844

8.  Synergistic effect of renalase and chronic kidney disease on endothelin-1 in patients with coronary artery disease ‒ a cross-sectional study.

Authors:  Yu-Hsuan Li; Wayne Huey-Herng Sheu; Wen-Jane Lee; Jun -Sing Wang; Chia-Po Fu; Kae-Woei Liang; I-Te Lee
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.